Orion (ORNBV) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
23 Apr, 2026Executive summary
All business divisions delivered strong Q1 2026 performance, with notable growth in Innovative Medicines and Branded Products, and positive clinical pipeline developments including ODM-212 receiving Orphan Drug Designation for mesothelioma from the FDA and initiation of the TEADCO phase 1b/2 trial.
Executive team strengthened with the appointment of a new EVP for Innovative Medicines.
Financial highlights
Net sales grew 17.8% year-over-year to €417.7 million in Q1 2026.
Operating profit rose 47.3% to €114.8 million, with an operating margin of 27.5%.
Earnings per share increased 47.4% to €0.64.
EBITDA reached €130.4 million (+42.5% YoY); profit for the period was €90.4 million (+47.6% YoY).
Cash flow from operating activities declined to €37.0 million due to increased working capital and tax payments.
Outlook and guidance
2026 net sales guidance raised to €1.95–2.1 billion (from €1.9–2.1 billion); operating profit guidance increased to €600–750 million (from €550–750 million).
Upgrade driven by strong Q1 performance and reduced downside risk from US pharma tariffs, now expected to impact no earlier than Q4.
Growth expected from NubeqaⓇ, Branded Products (especially Easyhaler®), and slight growth in Animal Health; R&D and sales/marketing expenses anticipated to rise.
Latest events from Orion
- Nubeqa-led growth lifted 9M sales 24.1% and operating profit 65.2%.ORNBV
Investor presentation - Nubeqa-led Q3 growth lifted operating profit 73.5% and drove higher FY26 guidance.ORNBV
Q3 2026 - AGM approved a EUR 1.62 dividend, Board changes and authority to issue up to 14 million shares.ORNBV
AGM 2024 - Innovative Medicines and Nubeqa® fuel robust growth, with strong profits and global expansion.ORNBV
Investor presentation - Strong H1 2026 growth driven by Innovative Medicines and Nubeqa royalties; outlook raised.ORNBV
Q2 2026 - Q2 2025 net sales rose 27% and operating profit 59%, driven by NubeqaⓇ and innovative medicines.ORNBV
Q2 2025 - Net sales and profit surged on Nubeqa® milestones, prompting an upgraded 2024 outlook.ORNBV
Q3 2024 - Strong H1 growth and upgraded 2024 outlook driven by Nubeqa, Animal Health, and milestone deals.ORNBV
Q2 2024 - Growth driven by innovation, global expansion, and new biologics pipeline.ORNBV
CMD 2025